

Certificate of Analysis for NR-41926

Klebsiella pneumoniae, Strain BIDMC 10

Catalog No. NR-41926

Product Description: *Klebsiella pneumoniae (K. pneumoniae)*, strain BIDMC 10 was isolated in 2009 from a human foot culture in Boston, Massachusetts, USA. *K. pneumoniae*, strain BIDMC 10 was deposited as a carbapenem-resistant strain and is part of a Carbapenem-Resistant Enterobacteriaceae (CRE) Sequencing Project at the Broad Institute. Strain BIDMC 10 was deposited as resistant to cefepime, ceftazidime, ceftriaxone and meropenem.

Lot¹: 70007983 Manufacturing Date: 11AUG2017

| TEST | SPECIFICATIONS | RESULTS |
|--|--|---|
| Phenotypic Analysis | | |
| Cellular morphology | Gram-negative rods | Gram-negative rods |
| Colony morphology ² | Report results | Circular, convex, entire, mucoid and cream (Figure 1) |
| Motility (wet mount) | Report results | Non-motile |
| VITEK® 2 Compact (GN card) | K. pneumonia (≥ 89%) | K. pneumonia (99%) ³ |
| Antibiotic Susceptibility Profile | | |
| VITEK® (AST-GN83)4 | | |
| Ampicillin | Report results | Resistant (≥ 32 µg/mL) |
| Amoxicillin/clavulanic acid | Report results | Resistant (≥ 32 µg/mL) |
| Ampicillin/sulbactam | Report results | Resistant (≥ 32 µg/mL) |
| Piperacillin/tazobactam | Report results | Resistant (≥ 128 µg/mL) |
| Cefazolin | Report results | Resistant (≥ 64 µg/mL) |
| Cefuroxime | Report results | Resistant (≥ 64 µg/mL) |
| Cefuroxime axetil | Report results | Resistant (≥ 64 µg/mL) |
| Cefoxitin | Report results | Resistant (= 32 µg/mL) |
| Cefotaxime | Report results | Resistant (= 8 µg/mL) |
| Ceftazidime | Resistant | Resistant (≥ 64 µg/mL) |
| Ceftriaxone | Resistant | Resistant (= 16 µg/mL) |
| Cefepime | Resistant | Resistant (≥ 2 µg/mL) |
| Aztreonam | Report results | Resistant (≥ 64 µg/mL) |
| Meropenem | Resistant | Resistant (≥ 16 µg/mL) |
| Amikacin | Report results | Resistant (≥ 64 µg/mL) |
| Gentamicin | Report results | Resistant (≥ 16 µg/mL) |
| Ciprofloxacin | Report results | Resistant (≥ 4 µg/mL) |
| Nitrofurantoin | Report results | Resistant (= 256 µg/mL) |
| Trimethoprim/sulfamethoxazole | Report results | Resistant (≥ 320 µg/mL) |
| Etest® antibiotic test strips ⁵ | · | |
| Ceftriaxone ⁶ | Resistant | Resistant (= 24 µg/mL) |
| Tobramycin ⁶ | Report results | Resistant (≥ 256 µg/mL) |
| Genotypic Analysis | | |
| Sequencing of 16S ribosomal RNA gene | ≥ 99% sequence identity to | 99.3% sequence identity to |
| (~ 750 base pairs) | K. pneumonia, strain BIDMC 10 | K. pneumonia, strain BIDMC 10 |
| - , | (GenBank: JNVG01000005.1) | (GenBank: JNVG01000005.1) ⁷ |
| Purity (post-freeze) ⁸ | Growth consistent with expected colony | Growth consistent with expected |
| | morphology | colony morphology |
| Viability (post-freeze) ² | Growth | Growth |

¹NR-41926 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

³Percent probabilities above 90% indicate a close match to the typical biochemical pattern for the given organism, with a percent probability of 99% being a perfect match between the test reaction pattern and the unique biochemical pattern of the given organism or organism group. For additional



Certificate of Analysis for NR-41926

information, please refer to O'Hara, C. M. and J. M. Miller. "Evaluation of the VITEK 2 ID-GNB Assay for Identification of Members of the Family Enterobacteriaceae and Other Nonenteric Gram-Negative Bacilli and Comparison with the VITEK GNI+ Card." <u>J. Clin. Microbiol.</u> 41 (2003): 2096-2101. PubMed: 12734254.

⁴Minimum Inhibitory Concentration (MIC); MIC interpretation was determined using VITEK® 2 software version 07.01 combined with the bioMérieux Advanced Expert System™ (AES) software using the interpretation standard CLSI M100-S22 (2012) and the interpretation guideline "Natural Resistance." For more information, please refer to Sanders, C. C., et al. "Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital." J. Clin. Microbiol. 39 (2001): 2379-2385. PubMed: 11427542.

⁵1 day at 37°C in an aerobic atmosphere on Mueller Hinton agar

⁶MIC Interpretation Guideline: CLSI M100-S22 (2012)

⁷Also consistent with other organisms

Figure 1: Colony Morphology



Date: 05 JAN 2018 Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

⁸Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with 5% CO₂ on Tryptic Soy agar.